After-hours movers: Alphabet, Levi, Paramount Global and more
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Apollo Global Management (APO) PT Raised to $122 at BMO Capital
April 5, 2024 6:31 AM EDTBMO Capital analyst Etinenne Ricard raised the price target on Apollo Global Management (NYSE: APO) to $122.00 (from $111.00) while maintaining a Outperform rating.
The analyst comments "Discussions with Apollo's management team focused on Athene's spread resiliency, distribution channel diversification, and the path... More
Paramount Global (PARA) upgraded at Wolfe Research following Skydance reports
April 4, 2024 12:55 PM EDTOn Thursday, Wolfe Research revised its rating on Paramount Global (NASDAQ: PARA), raising it to Peer Perform from Underperform. The adjustment reflects the firm's recognition of Paramount's asset strength and discretionary cash flow potential, which have been highlighted by recent press reports indicating a possible bidding war between Skydance and Apollo.
The speculation regarding Paramount's future gained momentum last spring following the company's dividend cut and a significant investment by BDT & MSD into National... More
Levi Strauss & Co. (LEVI) PT Raised to $22 at Goldman Sachs
April 4, 2024 7:15 AM EDTGoldman Sachs analyst Brooke Roach raised the price target on Levi Strauss & Co. (NYSE: LEVI) to $22.00 (from $14.00) while maintaining a Neutral rating.
The analyst comments "We step away from the quarter incrementally constructive on the stock as a result of sequentially improving... More
Levi Strauss & Co. (LEVI) PT Raised to $21 at Citi, 'A Good Start to The Yr w/Top-Line Tailwinds'
April 4, 2024 7:12 AM EDTCiti analyst Paul Lejuez raised the price target on Levi Strauss & Co. (NYSE: LEVI) to $21.00 (from $16.00) while maintaining a Neutral rating.
The analyst comments "LEVI posted a big EPS beat in 1Q, driven primarily by better GM. Revenues were inline with... More
Levi Strauss & Co. (LEVI) PT Raised to $20 at Morgan Stanley
April 4, 2024 6:42 AM EDTMorgan Stanley analyst Alex Straton raised the price target on Levi Strauss & Co. (NYSE: LEVI) to $20.00 (from $17.00) while maintaining a Equalweight rating.
The analyst comments "Better-than-expected 1Q results & an unchanged FY sales guide enabled LEVI stock to regain +7% after it traded down on... More
Levi Strauss & Co. (LEVI) PT Raised to $20 at Wells Fargo
April 4, 2024 5:45 AM EDTWells Fargo analyst Ike Boruchow raised the price target on Levi Strauss & Co. (NYSE: LEVI) to $20.00 (from $17.00) while maintaining a Equal Weight rating.
The analyst comments "With their first top-line beat in 12 months (and raised FY plan), new management is breaking... More
Stifel on MacroGenics (MGNX): 'incrementally more positive', 'We remain buyers into the next “by May 31” clinical update'
April 4, 2024 4:40 AM EDTStifel analyst Stephen Willey reiterated a Buy rating and $29.00 price target on MacroGenics (NASDAQ: MGNX).
The analyst comments "Were incrementally more positive on MGNX shares following managements disclosure of vobra-duo safety/tolerability data from the P2 TAMARACK trial contained within an... More
